-
2-APB as a Calcium-Signaling Assay Discriminator
2026-08-28
2-APB (2-aminoethoxydiphenyl borate) is more than an IP3R antagonist: it can help distinguish upstream PLCβ signaling from downstream calcium-entry phenotypes. This article develops an assay-centered framework linking 2-APB pharmacology to the sinapine–Gαq–PLCβ3 cardiovascular study.
-
Novel PDK4 Inhibitors for Metabolic Disease
2026-08-28
Lee and colleagues identified anthraquinone-derived allosteric inhibitors of pyruvate dehydrogenase kinase 4, highlighting compound 8c as a potent biochemical inhibitor with activity in metabolic, allergic, and cancer-related models. The study combines medicinal chemistry, biochemical testing, metabolic stability, pharmacokinetics, animal efficacy studies, and molecular docking to propose a new scaffold for PDK4-focused drug discovery.
-
Afatinib in Gastric Cancer Assembloid Assays
2026-08-27
Afatinib (BIBW 2992) can do more than suppress ErbB signaling: in patient-derived gastric cancer assembloids, it can help distinguish tumor-intrinsic dependence from stromal protection. This article presents an assay-centered framework for interpreting response, resistance, and translational relevance.
-
Cy5 Hydrazide for Carbonyl Labeling Workflows
2026-08-27
Cy5 hydrazide converts protein, glycoprotein, oligonucleotide, and selected nanoparticle carbonyls into far-red fluorescent readouts. This guide translates its chemistry into practical oxidative-stress, SDS-PAGE, and FAST nanoparticle workflows while addressing solubility, background, and labeling-specificity challenges.
-
Gepotidacin: Translational Leverage Against Resistance
2026-08-26
Gepotidacin, also known as GSK2140944, offers translational researchers a distinct way to interrogate bacterial DNA replication inhibition and resistance biology. This thought-leadership analysis connects its topoisomerase mechanism, assay strategy, pharmacokinetic evidence, and research-use implementation into a practical framework for antibacterial research.
-
RIPA Lysis Buffer (Strong) and Epigenetic Proof
2026-08-26
A translational framework for connecting prenatal glucocorticoid programming, MKP-1–MAPK biology, and reproducible protein-level evidence using strategically optimized lysis workflows.
-
Cefazedone–Etimicin PK: UFLC–MS/MS Study
2026-08-25
Cui and colleagues developed and validated an ultra-fast liquid chromatography–tandem mass spectrometry method for simultaneous measurement of cefazedone and etimicin in beagle dog plasma. The assay enabled a direct pharmacokinetic comparison of combined and single intravenous injections, with no obvious pharmacokinetic differences detected under the study conditions.
-
EZ Cap™ Firefly Luciferase mRNA Workflow
2026-08-25
Build sensitive reporter assays around Cap1-capped, polyadenylated luciferase mRNA, from RNase-controlled preparation through quantitative luminescence readout. The workflow also shows why delivery chemistry must be optimized independently for in vitro translation and in vivo imaging.
-
p-tau Ser356, NUAK Inhibition, and Alzheimer’s Disease
2026-08-24
The reference study links p-tau Ser356 to Braak stage, neurofibrillary tangles, and synaptic regions in Alzheimer’s disease brain tissue. Its ex vivo comparison further shows that NUAK inhibition produces distinct tau and neuronal responses in postnatal mouse versus adult human brain slice cultures, highlighting the importance of model context in therapeutic development.
-
GKT137831 for Nox1/Nox4 Redox Assays
2026-08-24
GKT137831 provides a practical way to separate Nox1/Nox4-driven reactive oxygen species signaling from downstream vascular, fibrotic, and ferroptosis-associated phenotypes. This workflow-focused guide covers dose selection, orthogonal readouts, controls, and troubleshooting for reproducible oxidative stress research.
-
Ferroptosis-Related lncRNAs in Pancreatic Cancer
2026-08-23
The reference study developed a nine-lncRNA ferroptosis-related signature for risk stratification in pancreatic adenocarcinoma and validated it across TCGA and ICGC cohorts. Its findings connect ferroptosis-associated transcriptional patterns with overall survival, immune infiltration, and potential immunotherapy response, while also highlighting the need for prospective and functional validation.
-
Eicosapentaenoic Acid: Applied Research Workflows
2026-08-22
Build reproducible Eicosapentaenoic Acid experiments around two differentiated endpoints: endothelial cell migration inhibition and low-micromolar lipoprotein oxidation control. This guide translates EPA membrane biology into practical assay design, troubleshooting, and carefully bounded comparisons with recent arachidonic acid immunology research.
-
Lipidated Nanophotosensitizer Disables Tumor EVs
2026-08-22
Miao and colleagues developed a palmitic-acid-displayed nanophotosensitizer that tracks tumor extracellular vesicles and generates reactive oxygen species inside both tumor cells and vesicles. The study shows how one light-activated platform can suppress primary tumors while disrupting TEV-mediated communication linked to metastasis, although translation beyond the tested preclinical models remains to be established.
-
Merbromin BA1653 for Reliable Assays
2026-08-21
Learn how Merbromin (SKU BA1653) can support protein-binding fluorescence studies, enzyme inhibition assays, and carefully controlled antimicrobial or antiviral screening workflows. This scenario-based guide emphasizes solvent compatibility, assay controls, interpretation, storage, and practical vendor selection.
-
DHHC9–STRN4 Palmitoylation Drives YAP Metastasis
2026-08-20
The reference study identifies a DHHC9–STRN4 palmitoylation–YAP axis that connects lipid modification to Hippo pathway dysregulation and adenocarcinoma metastasis. Its genetic, proteomic, and pharmacological evidence supports DHHC9 as a potential therapeutic target while also highlighting the need for better inhibitor selectivity and clinical validation.